BACKGROUND: Lichen planopilaris results in scaling, atrophy, and permanent alopecia with scarring and is thought to be autoimmune in origin. OBJECTIVE: To evaluate the clinical findings of patients with LPP so as to aid in the evaluation and diagnosis of the disease and to review the current effective therapies. METHODS: We reviewed the medical records of 29 patients with LPP that were seen in the Department of Dermatology at The Cleveland Clinic Foundation between 1992 and 2003. RESULTS: Good responses in the active perimeter were seen with topical steroids, intralesional steroids, and tetracycline and in the inactive end-stage with hair transplants and scalp reductions. LIMITATIONS: This study was limited by being retrospective in nature. CONCLUSION: Although topical high-potency and intralesional corticosteroids remain the mainstay for treatment of LPP, the use of tetracycline in this disease may be more helpful than once thought.
BACKGROUND: Lichen planopilaris results in scaling, atrophy, and permanent alopecia with scarring and is thought to be autoimmune in origin. OBJECTIVE: To evaluate the clinical findings of patients with LPP so as to aid in the evaluation and diagnosis of the disease and to review the current effective therapies. METHODS: We reviewed the medical records of 29 patients with LPP that were seen in the Department of Dermatology at The Cleveland Clinic Foundation between 1992 and 2003. RESULTS: Good responses in the active perimeter were seen with topical steroids, intralesional steroids, and tetracycline and in the inactive end-stage with hair transplants and scalp reductions. LIMITATIONS: This study was limited by being retrospective in nature. CONCLUSION: Although topical high-potency and intralesional corticosteroids remain the mainstay for treatment of LPP, the use of tetracycline in this disease may be more helpful than once thought.
Authors: Damia L Vendramini; Bruno R L Silveira; Bruna Duque-Estrada; Ana Letícia Boff; Celso Tavares Sodré; Rodrigo Pirmez Journal: Skin Appendage Disord Date: 2016-09-14
Authors: John S Barbieri; Ketaki Bhate; Kathleen P Hartnett; Katherine E Fleming-Dutra; David J Margolis Journal: JAMA Dermatol Date: 2019-03-01 Impact factor: 10.282